Patient Rating:

No Rating Available?

Gerhard Carl Hildebrandt, M.D., FACP

Specialties

Languages

  • English
  • German
  • Latin

Clinical Details

Locations

Schedule An Appointment Clinical Office Address
(801) 585-6906 Huntsman Cancer Hospital
Clinic 2C/BMT, Blood and Marrow Transplant
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

Gerhard Carl Hildebrandt, M.D. is Associate Professor of Medicine at the University of Utah and Director of the Utah Blood and Marrow Transplant Program. He received his medical degree from the Johannes Gutenberg University of Mainz Medical School, Germany, in 1997. For his doctoral research thesis he was awarded the “doctor medicinae” with magna cum laude. He then completed a residency in Internal Medicine and a Hematology and Oncology fellowship at the University of Regensburg, Germany. He was Bone Marrow Transplant and Hematologic Malignancies Attending at the University of Regensburg from 2008 – 2009, and in 2009 he was awarded the “Habilitation”, the highest academic qualification a scholar can achieve by own pursuit in Germany. In November 2009 he moved to the Louisiana State University Health Sciences Center in Shreveport as an Associate Professor of Medicine in the Division of Hematology and Oncology. From July 2011 until October 2012 he was Program Director of the Blood and Marrow Transplant Program at LSUHSC-Shreveport as well as Medical Director of the Stem Cell Laboratory.

Dr. Hildebrandt’s medical responsibilities at the “U” relate to autologous and allogeneic bone marrow transplantation and the care of patients with graft versus host disease. He is member of ASH, ASCO, ASBMT, AACR, the author of more than 40 articles, books and book chapters, and strongly involved in clinical trials.

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor (Clinical)
Academic Divisions Hematology/BMT

Academic Profile

Research Interests

  • Pathophysiology of Acute and Chronic Graft Versus Host Disease
  • Acute and Chronic Pulmonary Complications after Allogeneic Stem Cell Transplantation

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor (Clinical)
Academic Divisions Hematology/BMT

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 213-3718 Huntsman Cancer Institute
Hematology and Hematologic Malignancies
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Gerhard Carl Hildebrandt, M.D. is Associate Professor of Medicine at the University of Utah and Director of the Utah Blood and Marrow Transplant Program. He received his medical degree from the Johannes Gutenberg University of Mainz Medical School, Germany, in 1997. For his doctoral research thesis he was awarded the “doctor medicinae” with magna cum laude. He then completed a residency in Internal Medicine and a Hematology and Oncology fellowship at the University of Regensburg, Germany. He was Bone Marrow Transplant and Hematologic Malignancies Attending at the University of Regensburg from 2008 – 2009, and in 2009 he was awarded the “Habilitation”, the highest academic qualification a scholar can achieve by own pursuit in Germany. In November 2009 he moved to the Louisiana State University Health Sciences Center in Shreveport as an Associate Professor of Medicine in the Division of Hematology and Oncology. From July 2011 until October 2012 he was Program Director of the Blood and Marrow Transplant Program at LSUHSC-Shreveport as well as Medical Director of the Stem Cell Laboratory.

Dr. Hildebrandt’s participates in clinical trials in the field of bone marrow transplantation and graft versus host disease. His basic and clinical research interests focus on the prevention and treatment of graft versus host disease and lung injury after transplant. Dr. Hildebrandt is author of more than 40 articles, books and book chapters, and reviewer of several hematology and transplant journals.

Education

Education History

Type School Degree
Fellowship University of Regensburg Medical Center
Hematology and Oncology
Fellow
Residency University of Regensburg Medical Center
Internal Medicine /Hematology & Oncology
Resident
Fellowship University of Michigan Cancer Center, BMT Program
Postdoctoral Fellow
Residency University of Regensburg Medical Center
Internal Medicine
Resident
Doctoral Training Johannes Gutenberg-University Mainz Medical School
Thesis: Differentiation of alveolitis and pulmonary fibrosis in rabbits with MR imaging; ´magna cum laude’
Dr. med.
Professional Medical Johannes Gutenberg-University Mainz Medical School
Medicine, [Professional German Physician degree (equivalent to U.S. MD degree]
M.D.

Publications

Selected Provider Publications

Journal Article

  1. Beier, F, Arbter, K, Kittan, NA, Andreesen, R, Krause, SW, Holler, E, Hildebrandt, G(2014)Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as possible marker for improved clinical outcome.  Molecular and Clinical Oncology, 2(1),81-86
  2. Wolff, D, Ayuk, F, Elmaagacli, A, Bertz H, Lawitschka, A, Schleuning, M, Meyer, RG, Gerbitz, A, Hilgendorf, I, Hildebrandt, GC, Edinger, M, Klein, S, Halter, J, Mousset, S, Holler, E, Greinix, (2013)Current practice in diagnosis and treatment of acute graft-versus host-disease - results from a survey among German-Austrian-Swiss HSCT centers.  Biology of Blood and Marrow Transplantation, 19(5),767-76
  3. Palaniyandi, S, Radhakrishnan, SV, Karsson FJ, Stokes, KY, Kittan, N, Huber, E, Hildebrandt, G(2013)Murine cytomegalovirus immediate - early 1gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latend infection  PLoS ONE, 8(4),e61841
  4. Beier F, Beier CP, Aschenbrenner I, Hildebrandt GC, Brummendorf TH, Beier (2011)Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines.  Cellular & Molecular Neurobiology, 31(3),337-43
  5. Bouazzaoui A, Spacenko E, Mueller G, Huber E, Schubert T, Holler E, Andreesen R, Hildebrandt G(2011)Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract.  Experimental Hematology, 39(2),238-249.e1
  6. Bouazzaoui A, Spacenko E, Mueller G, Miklos S, Huber E, Holler E, Andreesen R, Hildebrandt G(2009)Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease.  Genes and Immunity, 10(8),687-701
  7. Reichle A, Hildebrandt G(2009)Principles of modular tumor therapy.  Cancer Microenvironment, 2 Suppl 1227-37
  8. Chang YY, Greinix HT, Dickinson AM, Wolff D, Jackson GH, Andreesen R, Holler E, Hildebrandt G(2009)G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation.  Cytokine, 48(3),218-25
  9. Miklos S, Mueller, G, Chang, Y, Bouazzaoui A, Spacenko, E, Schubert, TE, Grainger, DJ, Holler, E, Andreesen, R, Hildebrandt, G(2009)The usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host- disease.  International Journal of Hematology,
  10. Hildebrandt GC, Choi SW, Mueller G, Olkiewicz KM, Moore BB, Cooke K(2008)The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation.  Pediatric Blood & Cancer, 50(4),911-4
  11. Hildebrandt GC, Granell M, Urbano-Ispizua A, Wolff D, Hertenstein B, Greinix HT, Brenmoehl J, Schulz C, Dickinson AM, Hahn J, Rogler G, Andreesen R, Holler (2008)Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation.  Biology of Blood and Marrow Transplantation, 14(1),67-74
  12. Hildebrandt GC, Olkiewicz KM, Corrion L, Clouthier SG, Pierce EM, Liu C, Cooke K(2008)A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.  Biology of Blood and Marrow Transplantation, 14(4),385-96
  13. Miklos S, Mueller G, Chang Y, Schubert TE, Holler E, Hildebrandt G(2008)Pulmonary function changes in experimental graft-versus-host disease of the lung.  Biology of Blood and Marrow Transplantation, 14(9),1004-16
  14. Ewing P, Miklos S, Olkiewicz KM, Muller G, Andreesen R, Holler E, Cooke KR, Hildebrandt G(2007)Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.  Experimental Hematology, 35(1),155-63
  15. Choi SW, Hildebrandt GC, Olkiewicz KM, Hanauer DA, Chaudhary MN, Silva IA, Rogers CE, Deurloo DT, Fisher JM, Liu C, Adams D, Chensue SW, Cooke K(2007)CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation.  Blood, 110(9),3447-55
  16. Ewing P, Hildebrandt GC, Planke S, Andreesen R, Holler E, Gerbitz (2007)Cobalt protoporphyrine IX-mediated heme oxygenase-I induction alters the inflammatory cytokine response, but not antigen presentation after experimental allogeneic bone marrow transplantation.  International Journal of Molecular Medicine, 20(3),301-8
  17. Hildebrandt GC, Olkiewicz KM, Choi S, Corrion LA, Clouthier SG, Liu C, Serody JS, Cooke K(2005)Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation.  Blood, 105(6),2249-57
  18. Gerbitz A, Ewing P, Olkiewicz K, Willmarth NE, Williams D, Hildebrandt G, Wilke A, Liu C, Eissner G, Andreesen R, Holler E, Guo R, Ward PA, Cooke K(2005)A role for CD54 (intercellular adhesion molecule-1) in leukocyte recruitment to the lung during the development of experimental idiopathic pneumonia syndrome.  Transplantation, 79(5),536-42
  19. Hildebrandt GC, Duffner UA, Olkiewicz KM, Corrion LA, Willmarth NE, Williams DL, Clouthier SG, Hogaboam CM, Reddy PR, Moore BB, Kuziel WA, Liu C, Yanik G, Cooke K(2004)A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation.  Blood, 103(6),2417-26
  20. Hildebrandt GC, Olkiewicz KM, Corrion LA, Chang Y, Clouthier SG, Liu C, Cooke K(2004)Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation.  Blood, 104(2),586-93
  21. Hildebrandt GC, Corrion LA, Olkiewicz KM, Lu B, Lowler K, Duffner UA, Moore BB, Kuziel WA, Liu C, Cooke K(2004)Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome.  Journal of Immunology, 173(3),2050-9
  22. Gerbitz, A, Nickoloff, BJ, Olkiewicz, K, Willmarth, NE, Hildebrandt, GC, Liu, C, Kobzik, L, Eissner, G, Holler, E, Ferrara, JL, Cooke, K(2004)A role for tumor necrosis factor-alpha mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome.  Transplantation, 78(4),494-502
  23. Duffner U, Lu B, Hildebrandt GC, Teshima T, Williams DL, Reddy P, Ordemann R, Clouthier SG, Lowler K, Liu C, Gerard C, Cooke KR, Ferrara J(2003)Role of CXCR3-induced donor T-cell migration in acute GVHD.  Experimental Hematology, 31(10),897-902
  24. Reddy, P, Teshima, T, Hildebrandt, G, Williams, DL, Liu, C, Cooke, K, Ferrara, JL(2003)Pretreatment of donors with Interleukin-18 attenuates acute graft-versus-host diserase via STAT6 and preserves graft-versus-leukemia effects.  Blood, 101(7),2877-85
  25. Reddy P, Teshima T, Hildebrandt G, Duffner U, Maeda Y, Cooke KR, Ferrara J(2002)Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.  Blood, 100(9),3429-31
  26. Meric, F, Milas, M, Hunt, KH, Hess, KR, Pisters, PWT, Hildebrandt, G, Patel, SR, Benjamin, RS, Plager, C, Papadopolous, NEJ, Burgess, MA, Pollock, RE, Feig, B(2000)Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.  Journal of Clinical Oncology, 18(19),3378-83
  27. Schwab, L, Goroncy, L, Palaniyandi, S, Gautam, S, Triantafyllopoulou, A, Mocsai, A, Reichardt, W, Karsson, FJ, Radhakrishnan, SV, Hanke, K, Schmitt-Graeff, A, Freudenberg, M, von Loewenich, FD, Wolf, P, Leonhardt, F, Baxan, N, Pfeifer, D, Schmah, O, Schoenle, A, Martin, SF, Mertelsmann, R, Duyster, J, Finke, J, Prinz, M, Henneke, P, Haecker, H, Hildebrandt, GC, Haecker, G, Zeiser, R, LS, LG and SP contributed equally, GCH, GH and RZ contributed equally(In Press)Neutrophil Granulocytes Recruited Upon Translocation Of Intestinal Commensal Bacteria Enhance Graft-Versus-Host Disease Via Local Tissue Damage.  Nature Medicine,

Review

  1. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff (2011)Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.  Bone Marrow Transplantation, 46(10),1283-95
  2. Kittan NA, Hildebrandt G(2010)The chemokine system: a possible therapeutic target in acute graft versus host disease.  Current Topics in Microbiology and Immunology, 34197-120
  3. Wolff, D, Gerbitz, A, Ayuk, F, Kiani, A, Hildebrandt, GC, Vogelsang, GB, Elad, S, Lawitschka, A, Socie, G, Pavletic, SZ, Holler, E, Greinix (2010)Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD  Biology of Blood and Marrow Transplantation, 16(12),1611-28
  4. Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler (2009)Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.  Current Pharmaceutical Design (electronic), 15(17),1974-97
  5. Cooke, KR, Hildebrandt, (2006)Pulmonary toxicity following hematopoietic cell transplantation: Is the lung a target organ of graft-versus-host disease ?  Current Opinion in Organ Transplantation, 11(1),69-77

Book Chapter

  1. Munker R, Hildebrandt GC, Atkinson (2014)Acute myelogenous leukemia.  ,
  2. Reichle, A, Hildebrandt, G(2013)Applied Systems Biology for the Control of Metastatic Cancer: Purposive-Rational Tumor Therapy: Exploiting the Tumor's Living Word' for Diversifying, Specifying and Personalizing Tumor Therapy  , 261-288
  3. Reichle, A, Hildebrandt, G(2013)Applied Systems Biology for the Control of Metastatic Cancer: Therapeutic Top-Down Strategy for Targeting Tumors.  , 13-29
  4. Reichle, A, Hildebrandt, G(2013)Diversifying and Specifying Palliative Care for Patients with Metastatic Cancer by Therapeutic Implementation of Non-Normative Boundary Conditions.  , 365-396
  5. Reichle, A, Hildebrandt, G(2013)Evolution Theory: Its Practical Relevance for Understanding Tumor Development and Specifying Tumor Therapy.  , 191-238
  6. Hildebrandt GC, Munker R, Duffner U, Wolff D, Stadler M, Dietrich-Ntoukas T, Angstwurm K, Sun Al, Nair B, Lazarus HM, Atkinson (2013)Organ-related and miscellaneous complications.  ,
  7. Cooke, KR, Coghill, JM, Hildebrandt, GC, Serody, J(2012)Chemokines and graft-versus-host disease  , 393-424
  8. Reichle A, Vogt TH, Hildebrandt G(2010)A methodologically guided approach for personalized therapy in metastatic cancer. From molecular to modular tumor therapy: Tumors are reconstructible communicatively evolving systems. [ISBN: 978-90-481-9530-5].  , 3, Chapter 25507 – 536
  9. Reichle, A, Hildebrandt, G(2010)From molecular to modular, from theme-dependent to evolution-adjusted tumor therapy. From molecular to modular tumor therapy: Tumors are reconstructible communicatively evolving systems. [ISBN: 978-90-481-9530-5].  , 3, Chapter 27545 -556
  10. Reichle A, Hildebrandt G(2010)Principles of modular tumor therapy. From molecular to modular tumor therapy: Tumors are reconstructible communicatively evolving systems. [ISBN: 978-90-481-9530-5].  , 3, Chapter 329 – 50
  11. Reichle A, Hildebrandt G(2010)Searching for the ‘metabolism’ of evolution. From molecular to modular tumor therapy: Tumors are reconstructible communicatively evolving systems. [ISBN: 978-90-481-9530-5].  , 3, Chapter 14305 – 312
  12. Reichle A, Hildebrandt G(2010)The comparative uncovering of tumor systems biology by modularly targeting tumor-associated inflammation. From molecular to modular tumor therapy: Tumors are reconstructible communicatively evolving systems. [ISBN: 978-90-481-9530-5].  , 3, Chapter 13287 – 304
  13. Reichle A, Hildebrandt G(2010)To be an object in a biological system. From molecular to modular tumor therapy: Tumors are reconstructible communicatively evolving systems. [ISBN: 978-90-481-9530-5].  , 3, Chapter 26537 – 544

Case Report

  1. Devarakonda, SS, Shahan, JL, Takalkar, A, Chaudhery, SI, Jean, G, Koshy, NV, Hildebrandt, G(2013)Graft versus Lymphoma effect plus vorinostat as successful approach in a case of refractory gastric peripheral T cell lymphoma - not otherwise specified (PTCL-NOS) after reduced intensity conditioning (RIC)-allogeneic hematopoietic cell transplantation  Leukemia and Lymphoma, 54(11),2545-7
  2. Volodin, L, Peddi, P, Takalkar, A, Comeau, JM, Shahan, JL, Hildebrandt, G(2013)Successful treatment of first and second recurrence of Acute Lymphoblastic Leukemia after Related Allogeneic Bone Marrow Transplantation at unusual sites using single dose vincristine followed by interferon-alpha 2b and GM-CSF.  Leukemia and Lymphoma, 54(5),1107-9
  3. Shahan, JL, Panu, LD, Hildebrandt G(2012)Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.  International Journal of Hematology, 96(6),818-9

Letter

  1. Ammer J, Hahn J, Wolff D, Holler B, Landfried K, Hautmann A, Hamer OI, Schulz Ch, Hildebrandt G, Grube M, Andreesen R, Holler (2011)Immunomodulation by IFN-gamma in patients with resistant infections and accompanying bronchiolitis obliterans following allo-SCT.  Bone Marrow Transplantation, 46(5),756-8

Clinical Trials

Video & News